×

Stocks Pfizer Inc

  • Considering Pfizer, Sanofi and Glaxo are among the many Pharma names reporting this week, how should you game the space?

  • Markets started the new month higher, but how long can the trend continue? Art Cashin, director of floor operations at UBS Financial Services, shared his insights.

  • Brace for another round of big earnings, next week. And options action suggests Exxon, Cisco and Pfizer are poised to move.

  • First we found out bacon makes you smarter. Now, it may also make you sexier. Oh, bacon. Is there anything you can't do?

  • With the economy on the mend, the next few earnings seasons are set to give investors a good perspective on the trajectory of the overall economy, and individual company reports can do the same for specific segments of the market.  As earnings season comes to its midway point, Cramer has put together a list of 20 February 2010 earnings reports to watch; suggesting that if you pay close attention to these companies, you'll get a good handle on both the sector they represent and the overall health

    As earnings season comes to its midway point, Cramer put together a list of 20 February 2010 earnings reports. So, what are the most important earnings reports to watch?

  • clsa_cover.jpg

    Three out of four prescriptions in the U.S. are filled with generics. But a new, albeit small, survey by a prominent generic drug industry analyst shows even the people filling those pill bottles have issues with generics.

  • Markets opened mixed on Thursday. What should investors expect from stocks going forward? Ray Harrison, founder of Harrison Financial Group, and Bill Smead, CEO and CIO of Smead Capital Management, shared their investment plays.

  • Traders are coming to the realization that corporate America presented their most exciting earnings reports first in this earnings season.

  • If your investment strategy is ‘slow and steady wins the race,’ Pete Najarian has a trade for you.

  • Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • merck_entrance_200.jpg

    These have been sunny days for Merck. Setting aside today’s action, the stock’s been on a pretty good tear lately hitting levels not seen in nearly two years. But the sun isn’t shining everywhere within the company.

  • Following are the day’s biggest winners and losers. Find out why shares of Pfizer and El Paso popped while Sprint and Imax dropped.

  • Wall Street is closely watching the outcome of the special election in Massachusetts. It could have a big impact on the entire landscape in DC.

  • On Tuesday, the Fast Money traders were poring over results from IBM after big blue beat expectations but then sold-off in the after-market.

  • With a slew of banks set to report earnings this week, the Fast Money desk is closely watching the action in the financials. Is weakness already priced in?

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks edged lower at the open Friday, with investors unimpressed over earnings beats from Intel and JPMorgan Chase as well as economic readings in line with expectations.

  • Were you so preoccupied with tech on Thursday that you missed the important action in Pharma. If so, Pete Najarian has got you covered!

  • Sure you like his show, but what about his book? Peak inside the playbook of celebrity talk show titan, Regis Philbin.

  • Vivus is getting the JPMorgan Healthcare Conference off to a sexy start. The company announced this morning that its late-stage experimental erectile dysfunction drug apparently gets the job done in 15 minutes.

  • The traders are closely watching potential hot stocks ahead of the JPMorgan Health Care conference next week.